Skip to main content
Premium Trial:

Request an Annual Quote

GenomSys Raises CHF 9.3M in Series A Round

NEW YORK – GenomSys, a startup maker of DNA data processing software based in Switzerland, said today that it has closed a CHF 9.3 million ($9.3 million) Series A investment round. 

Geneva-based Preon Capital led the round, with participation from several European and American partners, including Elysia Capital, Dolby Family Ventures, and Susman Ventures. As a result of the investment, Dolby Family Ventures Managing Director Pascal Levensohn has joined the GenomSys board of directors.

GenomSys, founded in 2016 and headquartered in Lausanne, makes genomic analysis software based on the recently finalized MPEG-G data compression standard. Among other things, MPEG-G promises to give individuals access to genomic data and other aspects of personalized medicine on mobile devices, the company said.

The GenomSys software "will bring a dramatic reduction in genomic files' size, a faster information transfer, and more efficient data analysis," Cofounder Claudio Alberti said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.